Roche appoints head of translational oncology research

Roche has named William Pao, MD, PhD, as the Global Head of the Oncology Disease and Translational Area of their Pharma Research and Early Development division.

In his new role, Pao — professor of medicine and head of the division of hematology and oncology at the Vanderbilt University Medical Center — will direct the discovery and development of translational and innovative oncology medicine.

“William is recognized as one of the world's leading molecular oncologists, with world class expertise in targeted cancer therapeutics, translational medicine, molecular diagnostics, and personalized healthcare strategies using cancer genomics,” John Reed, MD, PhD, Global Head of Roche Pharma Research and Early Development, said in a press release. “His broad expertise provides Roche with a leader who will ensure our growth and who will position us for continued success as we strive to transform science into medicine.”

Pao also directed Vanderbilt’s Personalized Cancer Medicine Unit. He holds advisory roles with the NCI, American Association for Cancer Research and ASCO.

“I am excited to join Roche and feel privileged to help carry on Roche’s legacy in innovative cancer therapies,” Pao said. “I was particularly attracted to Roche as one of the pioneers and front-runners in personalized medicine, as the world’s top oncology company and the world’s largest in vitro diagnostics company, with a deep commitment to companion diagnostics coupled with targeted therapeutics. I look forward to the opportunity to make a meaningful impact for cancer patients as I work with my Roche colleagues.”